Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients With Severe Asthma Taking Tezepelumab

NCT06951867 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06951867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06951867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients With Severe Asthma Taking Tezepelumab
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
September 15, 2025
Completion date
May 31, 2029
Enrollment
16,640 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular events, mace